Similar articles

• Pure red-cell aplasia and epoetin therapy.

  Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio SM, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N. Bennett CL, et al. N Engl J Med. 2004 Sep 30;351(14):1403-8. doi: 10.1056/NEJMoa040528. N Engl J Med. 2004. PMID: 15459301
• Eprex-associated pure red cell aplasia and leachates.

  Schellekens H, Jiskoot W. Schellekens H, et al. Nat Biotechnol. 2006 Jun;24(6):613-4. doi: 10.1038/nbt0606-613. Nat Biotechnol. 2006. PMID: 16763579 No abstract available.
• Pure red-cell aplasia and recombinant erythropoietin.

  Gershon SK, Luksenburg H, Coté TR, Braun MM. Gershon SK, et al. N Engl J Med. 2002 May 16;346(20):1584-6; author reply 1584-6. doi: 10.1056/NEJM200205163462015. N Engl J Med. 2002. PMID: 12015400 No abstract available.
• Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group.

  Evens AM, Bennett CL, Luminari S. Evens AM, et al. Best Pract Res Clin Haematol. 2005;18(3):481-9. doi: 10.1016/j.beha.2005.01.017. Best Pract Res Clin Haematol. 2005. PMID: 15792923 Review.
• Pure red cell aplasia secondary to treatment with erythropoietin.

  Locatelli F, Del Vecchio L. Locatelli F, et al. J Nephrol. 2003 Jul-Aug;16(4):461-6. J Nephrol. 2003. PMID: 14696747 Review.